This product is a new type of non-narcotic analgesic, with mild antipyretic and muscle relaxant effects. Its chemical structure belongs to cyclized o-methylbenzylamine. Therefore, it does not have the characteristics of non-steroidal anti-inflammatory drugs, nor is it an opioid receptor agonist. It is effective for moderate and severe pain. An intramuscular injection of 20 mg of this product is equivalent to the effect of 12 mg of morphine. It has a mild respiratory depressant effect. It has no depressant effect on the circulatory system. There is no tolerance and dependence.

This product is an endogenous coenzyme B12, which participates in the one-carbon unit cycle and plays an important role in the transmethylation reaction of methionine synthesis from homocysteine. Animal experiments have found that this product is easier to enter neuronal organelles than cyanocobalamin, participates in the synthesis of thymidine nucleoside in brain cells and spinal cord neurons, promotes the utilization of folic acid and nucleic acid metabolism, and has a stronger effect on promoting nucleic acid and protein synthesis than cyanocobalamin. This product can promote axonal transport function and axonal regeneration, normalize the transport of axonal skeleton proteins in the sciatic nerve of diabetic rats induced by streptozotocin, and has an inhibitory effect on drug-induced neurodegeneration, such as neurodegeneration caused by adriamycin, acrylamide, and vincristine, and neurological diseases in spontaneously hypertensive rats. In rat tissue culture, it was found that this product can promote lecithin synthesis and neuronal myelination. This product can restore delayed synaptic transmission and neurotransmitter reduction to normal, restore end plate potential induction by increasing nerve fiber excitability, and restore acetylcholine in the brain of rats fed with choline-deficient feed to normal levels.

Eliminate free radicals and inhibit the release of inflammatory factors from various cells such as brain cells and vascular endothelial cells

Nateglinide is an amino acid derivative and an oral antidiabetic drug. It is used to treat patients with type 2 diabetes. The action of nateglinide depends on the binding and closure of the ATP-sensitive K particle channel receptor on the pancreatic β cell membrane, which depolarizes the cell, opens the calcium channel, and causes calcium influx, thereby stimulating insulin secretion and lowering blood sugar levels. The insulin secretion-promoting effect of nateglinide depends on the blood glucose level. When the glucose level is low, the insulin secretion-promoting effect is weakened. Nateglinide has a certain tissue selectivity and has a low affinity for myocardial and skeletal muscles.

Nateglinide is an amino acid derivative and an oral antidiabetic drug. It is used to treat patients with type 2 diabetes. The action of nateglinide depends on the binding and closing of the ATP-sensitive K particle channel receptor on the pancreatic beta cell membrane, which depolarizes the cell, opens the calcium channel, and causes calcium influx, thereby stimulating insulin secretion and lowering blood sugar levels. The insulin secretion-promoting effect of nateglinide depends on the blood glucose level. When the glucose level is low, the insulin secretion-promoting effect is weakened. Nateglinide has a certain tissue selectivity and has a low affinity for myocardial and skeletal muscles.